시장보고서
상품코드
1530993

섬유근육통 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Fibromyalgia Treatment Market (Treatment Type: Medications and Therapies, and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

발행일: | 리서치사: Transparency Market Research | 페이지 정보: 영문 123 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

이 보고서는 2024-2034년 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사하여 세계 섬유근육통 치료 시장을 조사했습니다. 이 보고서는 2024년을 기준 연도로, 2034년을 예측 연도로 하여 2018-2034년 세계 섬유근육통 치료 시장의 수익과 예측을 제공합니다. 또한 2024-2034년 세계 섬유근육통 치료 시장의 연평균 성장률(CAGR %)도 제시합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도자료, 관련 자료 등을 참고하여 섬유근육통 치료 시장을 추론했습니다.

시장 스냅샷
2023년 시장 규모 19억 달러
2034년 시장 규모 29억 달러
CAGR 3.8%

이 보고서는 세계 섬유근육통 치료 시장의 경쟁 환경을 조사하고 있습니다. 세계 섬유근육통 치료 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성별로 프로파일링되어 있습니다. 회사 개요, 재무 상태, 최근 동향, SWOT 등은 이 보고서에서 다루는 세계 섬유근육통 치료 시장 기업의 속성입니다.

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

  • 소개
  • 개요
  • 시장 역학
  • 세계의 시장 분석과 예측, 2017-2031년

제5장 주요 인사이트

  • 파이프라인 분석
  • 주요 제품/브랜드 분석
  • 주요 인수합병
  • COVID-19에 의한 산업에 대한 영향

제6장 세계의 시장 분석과 예측 : 치료 유형별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 치료 유형별, 2017-2031년
    • 의약품
    • 치료
  • 시장 매력 분석 : 치료 유형별

제7장 세계의 시장 분석과 예측 : 유통 채널별

  • 소개와 정의
  • 주요 조사 결과·발전
  • 시장 금액 예측 : 유통 채널별, 2017-2031년
    • 병원 약국
    • 소매 약국
    • 온라인 약국
  • 시장 매력 분석 : 유통 채널별

제8장 세계의 시장 분석과 예측 : 지역별

  • 주요 조사 결과
  • 시장 금액 예측 : 지역별, 2017-2031년
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카
  • 시장 매력 분석 : 지역별

제9장 북미의 시장 분석과 예측

제10장 유럽의 시장 분석과 예측

제11장 아시아태평양의 시장 분석과 예측

제12장 라틴아메리카의 시장 분석과 예측

제13장 중동 및 아프리카의 시장 분석과 예측

제14장 경쟁 상황

  • 시장 기업 - 경쟁 매트릭스(기업 계층과 규모별)
  • 시장 점유율 분석 : 기업별(2022년)
  • 기업 개요
    • Pfizer Inc.
    • Eli Lilly and Company
    • AbbVie Inc.
    • Tonix Pharmaceuticals
    • Aptinyx Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Sun Pharmaceutical Industries Limited
    • Astellas Pharma Inc.
    • Nipro Corporation
ksm 24.09.03

Fibromyalgia Treatment Market - Scope of Report

TMR's report on the global fibromyalgia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global fibromyalgia treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global fibromyalgia treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the fibromyalgia treatment market.

Market Snapshot
Market Value in 2023US$ 1.9 Bn
Market Value in 2034US$ 2.9 Bn
CAGR3.8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global fibromyalgia treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global fibromyalgia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global fibromyalgia treatment market.

The report delves into the competitive landscape of the global fibromyalgia treatment market. Key players operating in the global fibromyalgia treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global fibromyalgia treatment market profiled in this report.

Key Questions Answered in Global fibromyalgia treatment Market Report:

  • What is the sales/revenue generated by fibromyalgia treatment across all regions during the forecast period?
  • What are the opportunities in the global fibromyalgia treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Fibromyalgia Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global fibromyalgia treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global fibromyalgia treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global fibromyalgia treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fibromyalgia Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Fibromyalgia Treatment Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Fibromyalgia Treatment Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 6.3.1. Medications
      • 6.3.1.1. Pain Relievers
      • 6.3.1.2. Anti-Depressants
      • 6.3.1.3. Anti-Seizure Drugs
    • 6.3.2. Therapies
      • 6.3.2.1. Physical Therapy
      • 6.3.2.2. Occupational Therapy
      • 6.3.2.3. Counselling
  • 6.4. Market Attractiveness Analysis, by Treatment Type

7. Global Fibromyalgia Treatment Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Fibromyalgia Treatment Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2017-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Fibromyalgia Treatment Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 9.3.1. Medications
      • 9.3.1.1. Pain Relievers
      • 9.3.1.2. Anti-Depressants
      • 9.3.1.3. Anti-Seizure Drugs
    • 9.3.2. Therapies
      • 9.3.2.1. Physical Therapy
      • 9.3.2.2. Occupational Therapy
      • 9.3.2.3. Counselling
  • 9.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Value Forecast, by Country, 2017-2031
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Treatment Type
    • 9.6.2. By Distribution Channel
    • 9.6.3. By Country

10. Europe Fibromyalgia Treatment Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 10.3.1. Medications
      • 10.3.1.1. Pain Relievers
      • 10.3.1.2. Anti-Depressants
      • 10.3.1.3. Anti-Seizure Drugs
    • 10.3.2. Therapies
      • 10.3.2.1. Physical Therapy
      • 10.3.2.2. Occupational Therapy
      • 10.3.2.3. Counselling
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Treatment Type
    • 10.6.2. By Distribution Channel
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Fibromyalgia Treatment Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 11.3.1. Medications
      • 11.3.1.1. Pain Relievers
      • 11.3.1.2. Anti-Depressants
      • 11.3.1.3. Anti-Seizure Drugs
    • 11.3.2. Therapies
      • 11.3.2.1. Physical Therapy
      • 11.3.2.2. Occupational Therapy
      • 11.3.2.3. Counselling
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Treatment Type
    • 11.6.2. By Distribution Channel
    • 11.6.3. By Country/Sub-region

12. Latin America Fibromyalgia Treatment Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 12.3.1. Medications
      • 12.3.1.1. Pain Relievers
      • 12.3.1.2. Anti-Depressants
      • 12.3.1.3. Anti-Seizure Drugs
    • 12.3.2. Therapies
      • 12.3.2.1. Physical Therapy
      • 12.3.2.2. Occupational Therapy
      • 12.3.2.3. Counselling
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Treatment Type
    • 12.6.2. By Distribution Channel
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa Fibromyalgia Treatment Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Treatment Type, 2017-2031
    • 13.3.1. Medications
      • 13.3.1.1. Pain Relievers
      • 13.3.1.2. Anti-Depressants
      • 13.3.1.3. Anti-Seizure Drugs
    • 13.3.2. Therapies
      • 13.3.2.1. Physical Therapy
      • 13.3.2.2. Occupational Therapy
      • 13.3.2.3. Counselling
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Treatment Type
    • 13.6.2. By Distribution Channel
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Pfizer Inc.
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Eli Lilly and Company
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. AbbVie Inc.
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Tonix Pharmaceuticals
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Aptinyx Inc.
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Teva Pharmaceutical Industries Ltd.
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Novartis AG
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Sun Pharmaceutical Industries Limited
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Astellas Pharma Inc.
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Nipro Corporation
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제